Amman

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• Lung cancer1 trial
• Multiple sclerosis1 trial
• Myeloproliferative neoplasms1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 11 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Active, not recruiting

  A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

  NCT05456191· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

  NCT03591510· Phase 2· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

  NCT06075758· Novartis Pharmaceuticals· Source

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

  NCT03822468· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

  NCT03574545· Phase 1· Novartis Pharmaceuticals· Source